![]() |
Name |
(2Z)-2-[(4S,5S,6S,8S,9S,10R,13R,14S,16S)-16-acetyloxy-6-hydroxy-4,8,10,14-tetramethyl-3,7-dioxo-5,6,9,11,12,13,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
|
Molecular Formula | C31H42O7 | |
IUPAC Name* |
(2Z)-2-[(4S,5S,6S,8S,9S,10R,13R,14S,16S)-16-acetyloxy-6-hydroxy-4,8,10,14-tetramethyl-3,7-dioxo-5,6,9,11,12,13,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
|
|
SMILES |
C[C@H]1[C@@H]2[C@@H](C(=O)[C@]3([C@H]([C@]2(C=CC1=O)C)CC[C@@H]\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\C(=O)O)OC(=O)C)C)C)O
|
|
InChI |
InChI=1S/C31H42O7/c1-16(2)9-8-10-19(28(36)37)24-20-11-12-23-29(5)14-13-21(33)17(3)25(29)26(34)27(35)31(23,7)30(20,6)15-22(24)38-18(4)32/h9,13-14,17,20,22-23,25-26,34H,8,10-12,15H2,1-7H3,(H,36,37)/b24-19-/t17-,20+,22+,23+,25-,26+,29-,30+,31-/m1/s1
|
|
InChIKey |
ZGQQEJUGWPCCHA-SIZJDIOISA-N
|
|
Synonyms |
Helvolinic acid
|
|
CAS | NA | |
PubChem CID | 139588222 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 526.7 | ALogp: | 4.5 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 118.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 38 | QED Weighted: | 0.286 |
Caco-2 Permeability: | -5.354 | MDCK Permeability: | 0.00002270 |
Pgp-inhibitor: | 0.967 | Pgp-substrate: | 0.823 |
Human Intestinal Absorption (HIA): | 0.04 | 20% Bioavailability (F20%): | 0.061 |
30% Bioavailability (F30%): | 0.937 |
Blood-Brain-Barrier Penetration (BBB): | 0.956 | Plasma Protein Binding (PPB): | 93.23% |
Volume Distribution (VD): | 0.445 | Fu: | 8.21% |
CYP1A2-inhibitor: | 0.01 | CYP1A2-substrate: | 0.117 |
CYP2C19-inhibitor: | 0.019 | CYP2C19-substrate: | 0.574 |
CYP2C9-inhibitor: | 0.047 | CYP2C9-substrate: | 0.068 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.057 |
CYP3A4-inhibitor: | 0.225 | CYP3A4-substrate: | 0.2 |
Clearance (CL): | 3.278 | Half-life (T1/2): | 0.268 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.326 |
Drug-inuced Liver Injury (DILI): | 0.448 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.835 | Maximum Recommended Daily Dose: | 0.034 |
Skin Sensitization: | 0.318 | Carcinogencity: | 0.37 |
Eye Corrosion: | 0.073 | Eye Irritation: | 0.047 |
Respiratory Toxicity: | 0.945 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001480 | ![]() |
0.826 | D0X7XG | ![]() |
0.527 | ||
ENC005487 | ![]() |
0.805 | D0G7KJ | ![]() |
0.293 | ||
ENC005155 | ![]() |
0.802 | D09WYX | ![]() |
0.286 | ||
ENC003484 | ![]() |
0.732 | D0E9KA | ![]() |
0.280 | ||
ENC005236 | ![]() |
0.696 | D0D2TN | ![]() |
0.279 | ||
ENC005154 | ![]() |
0.696 | D01ZOG | ![]() |
0.277 | ||
ENC002467 | ![]() |
0.654 | D0H2MO | ![]() |
0.273 | ||
ENC003848 | ![]() |
0.626 | D0X2LV | ![]() |
0.272 | ||
ENC003846 | ![]() |
0.608 | D09IEE | ![]() |
0.271 | ||
ENC005151 | ![]() |
0.577 | D0F7NQ | ![]() |
0.270 |